breast-cancer

Targeted nanoparticles home in on specific breast cancer receptors to improve paclitaxel delivery.

This review focuses on surface-functionalized polymeric nanoparticles for active targeting of breast cancer cells. Ligands like folic acid (folate receptor), hyaluronic acid (CD44), aptamers, and peptides (HER2) enable receptor-mediated endocytosis, improving drug delivery to cancer cells while…

Targeted nanoparticles home in on specific breast cancer receptors to improve paclitaxel delivery.

Key Findings

Surface functionalization enables receptor-targeted paclitaxel delivery to breast cancer cells
Target receptors include folate receptor, CD44, and HER2—all overexpressed in BC
Receptor-mediated endocytosis increases intracellular drug delivery
Next-generation designs incorporate multifunctionality and optimized ligand density
Addresses paclitaxel's clinical limitations of poor solubility and systemic toxicity

Implications

Surface-engineered nanoparticles could improve breast cancer treatment by delivering higher drug concentrations to tumors with fewer side effects.

Caveats

Review article; abstract-only. Most supporting studies in cell lines or animal models. Clinical translation is a major challenge.

Source: AAPS PharmSciTech — 2026-04-10

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Targeted nanoparticles home in on specific breast cancer receptors to improve paclitaxel delivery.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database